文献速递肾小球疾病慢性肾脏病

干扰素基因刺激因子(STING)激活导致蛋白尿并参与肾小球疾病

Activation of Stimulator of IFN Genes (STING) Causes Proteinuria and Contributes to Glomerular Diseases.
PubMed 文献 · J Am Soc Nephrol · 2022-10-05

研究在体外分化的足细胞及db/db糖尿病小鼠、实验性Alport综合征小鼠、C57BL/6小鼠和STING敲除小鼠中探讨STING信号通路的作用。结果显示STING激活使C57BL/6小鼠出现白蛋白尿和足细胞丢失,遗传或药理抑制STING可保护DKD和Alport综合征小鼠免于肾病进展并延长Alport综合征小鼠寿命。

要点

  • 小鼠和人足细胞表达cGAS-STING通路全部组分。
  • STING激活使C57BL/6小鼠易出现白蛋白尿和足细胞丢失。
  • 遗传或药理抑制STING可保护DKD和Alport综合征小鼠肾病进展。

核心结论

  • STING通路激活是DKD和Alport综合征疾病进展的介质。
  • 靶向STING可能为治疗代谢性和非代谢性肾小球疾病或预防其发生、进展提供治疗选择。

研究设计与样本

  • 体外:永生化人及小鼠足细胞分化14天后用STING特异性激动剂处理。
  • 体内:使用糖尿病db/db小鼠、实验性Alport综合征小鼠、C57BL/6小鼠和STING敲除小鼠评估STING信号通路在肾衰竭中的作用。

主要发现

  • 体外小鼠和人足细胞表达cGAS-STING通路全部组分。
  • 体内STING激活使C57BL/6小鼠易出现白蛋白尿和足细胞丢失。
  • 实验性DKD和Alport综合征小鼠基线时STING即被激活。
  • STING激活发生于肾小球而非肾小管间质区室,Alport综合征小鼠伴足细胞自噬性死亡,DKD小鼠模型伴足细胞凋亡性死亡。
  • 遗传或药理抑制STING可保护DKD和Alport综合征小鼠免于肾病进展,并延长Alport综合征小鼠寿命。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The signaling molecule stimulator of IFN genes (STING) was identified as a crucial regulator of the DNA-sensing cyclic GMP-AMP synthase (cGAS)-STING pathway, and this signaling pathway regulates inflammation and energy homeostasis under conditions of obesity, kidney fibrosis, and AKI. However, the role of STING in causing CKD, including diabetic kidney disease (DKD) and Alport syndrome, is unknown. METHODS: To investigate whether STING activation contributes to the development and progression of glomerular diseases such as DKD and Alport syndrome, immortalized human and murine podocytes were differentiated for 14 days and treated with a STING-specific agonist. We used diabetic db/db mice, mice with experimental Alport syndrome, C57BL/6 mice, and STING knockout mice to assess the role of the STING signaling pathway in kidney failure. RESULTS: In vitro, murine and human podocytes express all of the components of the cGAS-STING pathway. In vivo, activation of STING renders C57BL/6 mice susceptible to albuminuria and podocyte loss. STING is activated at baseline in mice with experimental DKD and Alport syndrome. STING activation occurs in the glomerular but not the tubulointerstitial compartment in association with autophagic podocyte death in Alport syndrome mice and with apoptotic podocyte death in DKD mouse models. Genetic or pharmacologic inhibition of STING protects from progression of kidney disease in mice with DKD and Alport syndrome and increases lifespan in Alport syndrome mice. CONCLUSION: The activation of the STING pathway acts as a mediator of disease progression in DKD and Alport syndrome. Targeting STING may offer a therapeutic option to treat glomerular diseases of metabolic and nonmetabolic origin or prevent their development, progression, or both.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Mitrofanova A, Fontanella A, Tolerico M, et al. Activation of Stimulator of IFN Genes (STING) Causes Proteinuria and Contributes to Glomerular Diseases. J Am Soc Nephrol. 2022. PMID: 36198430. doi:10.1681/ASN.2021101286

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。